Eric Weinberg
Known title: Chief Commercial OfficerCIK: 0001295814
Associated companies
Transaction History
| RXST | ▲ Buy | Option Exercise | 35,168 | $153K | 9/15/2026 | View on chart |
| RXST | ▼ Sell | Open Market | 2,041 | $14K | 9/2/2026 | View on chart |
| RXST | ▲ Buy | Option Exercise | 5,370 | — | 8/31/2026 | View on chart |
| RXST | ▲ Buy | Option Exercise | 188,002 | $739K | 6/2/2025 | View on chart |
| RXST | ▼ Sell | Open Market | 10,000 | $500K | 2/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 10,000 | $480K | 1/22/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 10,000 | $460K | 1/9/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 10,000 | $420K | 1/8/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 1,285 | $51K | 12/22/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 8,715 | $349K | 12/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.